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group to the M+P group.
Study design
This study used a multi-centre (three Canadian hospitals) crossover, randomised, controlled, trial design. Patients were followed-up from the start of treatment until death. The median survival follow-up time was 11 months. The authors did not report whether any patients were lost to follow-up in this economic study. At the time of resource collection, six of the 114 patients were alive (4 in the M+P group and 2 in the P group). The authors did not report the method used to mask participants (health care professionals and patients) or health care investigators to treatment allocation for the assessment of outcomes.
Analysis of effectiveness
The basis for the analysis of the clinical study (intention to treat or treatment completers only) was not stated. The primary health outcome was a palliative response, which was measured by a two-point reduction in a six-point scale completed by the patients without an increase in analgesic medication, and maintained for two consecutive evaluations at least three weeks apart.
The groups were comparable in terms of survival and baseline patient characteristics. There was a tendency for the M+P group to have a higher baseline analgesic score, (p<0.003).
Effectiveness results
The M+P group were more likely to have a palliative response (23 of the 80 patients (29%), 95% CI: 19 -40 patients) compared to the P group (10 of the 81 patients (12%), 95% CI: 6 -22 patients, p<0.01).
Eleven of the 50 patients initially randomised to the P group responded after the addition of mitoxantrone.
Clinical conclusions
The authors concluded that M+P results in a clinically and statistically significant proportion of patients with HRPC achieving pain relief.
Modelling
Survival curves were reported for the two treatment arms.
The mean cumulative costs for the two initially randomised groups were plotted as a function of time. This was necessary because the study used a crossover design and the two treatment arms did not have comparable time periods. The authors explained that in this trial there was no fixed time period at which the two treatment arms could be compared without the confounding effect of the crossover.
Measure of benefits used in the economic analysis
Quality-adjusted life years (QALYs) were used as the measure of benefit in the economic analysis. Patients in the trial completed the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 global quality of life rating scale questionnaire every three weeks. The quality of life scale was transformed to give an estimate of utility using a published transformation formula: utility = 1.07 x rating scale value (R) for R<0.95, 1.00 x R for R>0.95. This transformation was used to account for the lower utility obtained when a person described quality of life without risking any possible loss to that individual.
Direct costs
Quantities and costs were not reported separately. The time horizon started from randomisation until death (n=108 patients) or last recorded follow-up (n=6 patients who were still alive at the end of the study). The direct costs included were: days of inpatient admissions (cancer centre, intensive care unit, community hospital, hospice); outpatient clinics; day care; chemotherapy; radiation therapy; hormonal therapy; outpatient drugs; diagnostic and laboratory investigations. Homecare costs and costs to patients and their families were not included in the analysis. The estimation of the quantities was based on a chart review and was recorded by date, which could be related to the randomisation date. The estimation of each of the direct costs was based on: admission to a cancer centre in the Princess Margaret Hospital in Toronto using the hotel method; physician services with the Ontario Health Insurance Plan (OHIP) fee schedule; OHIP fee schedule for investigations; Ontario Drug Benefit formulary; published review of external beam radiation; blood products from the Canadian Red Cross Society; and OHIP for surgery staff costs.
The quantity of resources was measured between June and October 1996. The price year was 1996. Costs were corrected to 1996 prices using the Statistics Canada Consumer Price Index for all items. Discounting was, appropriately, not carried out, due to the short time-frame (less than one-year) of the study.
Statistical analysis of costs
Costs were analysed using Student's t test, a log transformation and non-parametric statistical tests. The authors only reported the Student's t tests because the results with each type of test were similar.
Indirect Costs
Indirect costs were not reported.
Currency
Canadian dollars (Can$). The baseline analysis was repeated using cost estimates derived from an American academic centre and Canadian costs were converted to US$, using the 1996 exchange rate (US$0.73 = Can$1).
Sensitivity analysis
One-way sensitivity analyses were carried out using the following input parameters: inpatient and outpatient costs (varied by 25%); laboratory and diagnostic costs (varied by 50%); surgery costs (varied by 500%).
Estimated benefits used in the economic analysis
There was a mean of 41.5 quality-adjusted weeks associated with the M+P group and 28.2 quality-adjusted weeks associated with the P group.
The incremental benefits were 13.3 quality-adjusted weeks per patient for the strategy of initial mitoxantrone (M+P).
Cost results
The mean total cost from randomisation to death was Can$27,300 (US$ 21,900) for patients randomised to the M+P group.
The mean total cost from randomisation to death was Can$29,000 (US$ 23,350) for patients randomised to the M+P group.
Synthesis of costs and benefits
The M+P group resulted in an overall cost saving of Can$1,700 per patient (95% CI: -Can$9,200 to +Can$5,800) and an additional 13.3 quality-adjusted weeks. It was therefore not relevant to calculate an incremental cost-utility ratio for the baseline analysis.
An incremental analysis was performed for the upper 95% CI for the cost estimate (Can$5,800) of the M+P strategy and the value was Can$19,700 per QALY gained.
The approach used to analyse the effectiveness data, in terms of treatment completers or intention to treat, was not reported. The study did not report any power calculations. It was therefore not possible to determine if the study sample was adequate to detect statistical differences in effectiveness.
Validity of estimate of measure of benefit
The summary measure of benefit was quality-adjusted life weeks. The value of survival was estimated as utility, which was based on transformed quality-adjusted life year valuations and appeared to be appropriate for the study question.
Validity of estimate of costs
All categories of costs relevant to the study perspective were included in the analysis. The authors explained that costs to the family doctor and homecare costs were omitted from the analysis because it was not possible to value them accurately. Indirect costs were also omitted from the analysis. The authors did not suggest whether this omission would affect the conclusions reached from the results of the study.
Costs and quantities were not reported separately. It is not clear if unit costs or charges were used to value costs. The study included a statistical analysis of cost data. The authors suggest that the study sample was based on a clinical outcome measure rather than cost data and that the study may not have been large enough to detect a statistical difference in costs. The authors compared two approaches for the analysis of the cost data because these were positively skewed and presented the results of a parametric test, the Student's t test. Fieller's theorem was used to estimate 95% confidence intervals around the cost and utility data. An alternative approach would have been to use non-parametric bootstrapping but the economic literature is not clear regarding which approach should be used. A sensitivity analysis of costs was conducted using appropriate ranges of the input parameters. The study did not explore the sensitivity of the results to utility estimates, which may affect the generalisability of the benefit measure. The authors explored the impact of using North American rather than Canadian price estimates. All costs were incurred over one year and discounting was, therefore, unnecessary.
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